FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per respons | e 0.5 | | | | | | | | |

to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b).

| Name and Address of Reporting Person* Chacko Jacob | | | | 2. Issuer Name and Ticker or Trading Symbol Oric Pharmaceuticals, Inc. [ORIC] | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | |
|--|---|--|--------------|---|--|--|------------------|---------------------------------------|----------------------------------|---------------------|--|--|---|--|---------------------------------------|--|--|--|--|
| CHacko Jacob | | | | | | | | | | | | - | | X | Direc | tor | | 10% Ov | vner |
| (Last) | Last) (First) (Middle) | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 02/06/2024 | | | | | | | | X | belov | , | | Other (s below) | specify |
| C/O ORIC PHARMACEUTICALS, INC. | | | | | | 02/00/2021 | | | | | | | | | Pl | RESIDEN' | ΓA | ND CEO | |
| 240 E. GRAND AVE., 2ND FLOOR | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| (Street) | | | | | | | | | | | | | | X | X Form filed by One Reporting Person | | | | |
| SOUTH | OUTH SAN LANCISCO CA 94080 | | | | | | | | | | | | | Form filed by More than One Reporting Person | | | | | |
| TRAINCISCO | | | | | Ru | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | |
| (City) | (Sta | ate) (7 | Zip) | | '`` | .0 .0 | ,,,, | . (0 | , | arioa | 000011111 | a. | 011 | | | | | | |
| (Oily) | y) (Gialo) (Zip) | | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | |
| | | Table | I - I | Non-Deriva | tive | Secui | rities | Ac | quir | ed, Di | sposed o | of, or | Benefic | ially | Own | ed | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye | | | | Execution D | | n Date, Tr | | Transaction Disposed Of (Code (Instr. | | Acquire (D) (Ins | Acquired (A) or D) (Instr. 3, 4 and | | Securi Benefi | ities Fricially (I d Following In | | m: Direct or rect (I) | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | С | | Code | v | Amount | (A) or (D) | Price | | Transa | ransaction(s) | | tr. 4) | (Instr. 4) |
| Common Stock 02/06/202- | | | | 4 | | | S ⁽¹⁾ | | 13,958 | D | \$12.1192 ⁽²⁾ | | 794,586 | | | D | | | |
| Common Stock 02/07/2024 | | | | 4 | | 5 | | S ⁽¹⁾ | | 26,042 | D | \$12.29 | 95 ⁽³⁾ | 768,544 | | | D | | |
| | | Tal | ole I | II - Derivati | | | | | | | | | | | Owne | d | | | |
| | | | | (e.g., pu | ıts, c | alls, v | warra | ints | , op | tions, | converti | ble se | curities | s) | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | Exe if ar | Deemed cution Date, ny nth/Day/Year) | | ransaction of ode (Instr. Derivative | | | Expiration Date (Month/Day/Year) | | | Amo Secu Undo Deriv Secu | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | rice of ivative urity tr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | | Code | Code V (A) (D) | | | Date Expiration Exercisable Date | | ı Title | Amount or Number of Shares | | | | | | | |

Explanation of Responses:

- 1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022.
- 2. Represents the weighted average share price of an aggregate total of 13,958 shares sold in the price range of \$12.00 to \$12.31 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 3. Represents the weighted average share price of an aggregate total of 26,042 shares sold in the price range of \$12.11 to \$12.40 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

/s/ Christian Kuhlen, attorney-02/08/2024 in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.